CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 317 enrolled
Drug / intervention
Zinforo (ceftaroline fosamil)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04198571
NCT04198571N/ACompleted
CompareCT.gov

MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalised for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue Infections (cSSTI) Treated With Zinforo (REGISTERED) (Ceftaroline Fosamil) in a Usual Care Setting

Pfizer·observational·Posted Dec 13, 2019·Updated Mar 26, 2024

In Brief

An observational study evaluating Zinforo (ceftaroline fosamil) for Community Acquired Pneumonia and Complicated Skin and Soft Tissue Infection. Completed, enrolled 317 participants across 26 sites in 7 countries.

Detailed Summary

MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue Infections (cSSTI) Treated with Zinforo® (ceftaroline fosamil) in a Usual Care Setting

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCommunity Acquired Pneumonia, Complicated Skin and Soft Tissue Infection
CountriesBrazil, Colombia, France, Greece, Italy, Russia, Spain
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 13, 2019
Enrollment StartMay 17, 2020
Primary CompletionJul 23, 2021
Study CompletionAug 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.6 years ago

Interventions

Zinforo (ceftaroline fosamil)drug

IV Solution